List of Excipients in Branded Drug COPIKTRA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Verastem Inc	COPIKTRA	duvelisib	71779-125	CELLULOSE, MICROCRYSTALLINE	2032-09-24
Verastem Inc	COPIKTRA	duvelisib	71779-125	CROSPOVIDONE	2032-09-24
Verastem Inc	COPIKTRA	duvelisib	71779-125	MAGNESIUM STEARATE	2032-09-24
Verastem Inc	COPIKTRA	duvelisib	71779-125	SILICON DIOXIDE	2032-09-24

COPIKTRA Excipient Strategy and Commercial Opportunities

Last updated: August 3, 2026

COPIKTRA (duvelisib) is an oral PI3K-delta/PI3K-gamma inhibitor supplied as immediate-release capsules in 15 mg and 25 mg strengths. Its current commercial opportunity is less likely to come from a simple generic capsule than from differentiated formulations, excipient substitution, lifecycle management, and supply-chain improvements for patients with relapsed hematologic malignancies.

The U.S. product uses a conventional solid-dose platform built around lactose, microcrystalline cellulose, croscarmellose sodium, magnesium stearate, colloidal silicon dioxide, sodium lauryl sulfate, and talc, with a gelatin capsule shell and colorants.[1] The excipient profile creates openings for lactose-free, surfactant-reduced, sprinkle-compatible, and potentially liquid or multiparticulate formulations.

What excipients are used in COPIKTRA capsules?

The U.S. prescribing information identifies the following core inactive ingredients in COPIKTRA capsules:[1]

Excipient	Likely formulation role	Commercial relevance
Lactose monohydrate	Diluent and bulking agent	Creates an opening for lactose-free reformulation
Microcrystalline cellulose	Diluent and compression or filling aid	Standard, low-risk replacement platform
Croscarmellose sodium	Superdisintegrant	Supports rapid capsule-content dispersion
Magnesium stearate	Lubricant	Can affect wetting and dissolution at higher levels
Colloidal silicon dioxide	Glidant and moisture-flow aid	Supports powder flow and manufacturing consistency
Sodium lauryl sulfate	Wetting agent and surfactant	Potential tolerability and formulation-differentiation target
Talc	Processing aid and anti-adherent	May be replaceable in a clean-label or regional strategy
Gelatin	Capsule-shell material	Limits vegetarian and some religious-market positioning
Titanium dioxide and capsule colorants	Opacity and product identification	Relevant to regional excipient compliance and colorant substitution

The listed formulation is a conventional hard-gelatin capsule rather than a controlled-release, enteric-coated, lipid-based, or depot system. That simplicity lowers manufacturing complexity but also leaves fewer obvious barriers to a conventional generic product.

What is the role of lactose in COPIKTRA?

Lactose monohydrate provides volume and supports powder handling. It is widely used in oral solid dosage forms, but it creates three commercial constraints:

1. Patients with severe lactose intolerance may seek an alternative.
2. Some jurisdictions and institutional buyers prefer lactose-free products.
3. Lactose can participate in degradation reactions with susceptible drug substances containing reactive functional groups.

A lactose-free formulation could replace lactose with microcrystalline cellulose, mannitol, dibasic calcium phosphate, or another compatible filler. The replacement would require comparative dissolution, impurity, moisture, capsule-fill, and stability studies. A lactose-free label alone would generally have limited pricing power unless linked to a clinically meaningful tolerability or access advantage.

Why is sodium lauryl sulfate commercially relevant?

Sodium lauryl sulfate improves wetting and can help disperse a poorly wettable active ingredient. It can also contribute to gastrointestinal sensitivity in some formulations. Removing or reducing it may be commercially attractive, but the change would need to preserve dissolution across physiological pH conditions and maintain content uniformity.

Potential substitutes include polysorbates, poloxamers, sodium docusate, lecithin, or particle-size and surface-area engineering. Each substitute introduces a new impurity, oxidation, compatibility, or regulatory-control question. The strongest opportunity is not simply "SLS-free" labeling. It is a formulation that demonstrates equivalent or improved dissolution without increasing variability after storage.

What formulation opportunities exist for duvelisib?

The highest-value opportunities are patient-specific dosage forms and excipient systems that improve administration, stability, or adherence.

Lactose-free and low-surfactant capsules

This is the lowest technical-risk opportunity. A developer could retain the immediate-release capsule architecture while replacing lactose and reducing or eliminating sodium lauryl sulfate.

The commercial advantages would include:

• Broader use in patients avoiding lactose.
• A differentiated inactive-ingredient profile.
• Potentially improved procurement eligibility in hospitals or specialty pharmacies.
• A formulation patent opportunity if the excipient ratios produce unexpected stability or dissolution results.

The weakness is substitutability. A conventional generic developer may avoid the cost of a separate formulation if the reference formulation is straightforward to reproduce.

Sprinkle or capsule-opening formulation

Patients with dysphagia, treatment-related weakness, or difficulty swallowing capsules may benefit from a capsule that can be opened and administered over soft food. A sprinkle product would require control of:

• Drug distribution within the capsule.
• Particle-size and powder segregation.
• Taste and odor.
• Food compatibility.
• Stability after opening.
• Occupational exposure during handling.
• Dose recovery from the administration vehicle.

The current reference labeling should not be interpreted as authorizing capsule opening unless the FDA label specifically permits that method. A sprinkle version would therefore represent a new product-development program rather than a simple labeling modification.

Oral liquid or reconstitutable suspension

A liquid duvelisib product could address swallowing limitations and support dose flexibility. The technical burden is materially higher than for a capsule. Duvelisib solubility, chemical stability, precipitation risk, preservative compatibility, and container adsorption would control the development path.

Commercial applications include:

• Patients unable to swallow capsules.
• Specialty-care settings requiring dose adjustment.
• Hospital or palliative-care use.
• Pediatric or adolescent hematology, if clinically appropriate.
• Markets where liquid oncology formulations have stronger institutional demand.

An oral liquid could command a higher price than a lactose-free capsule, but it would carry greater manufacturing, packaging, stability, and regulatory costs.

Multiparticulate and modified-release systems

Duvelisib is currently an immediate-release capsule. A multiparticulate formulation could improve dose flexibility and reduce variability without necessarily changing the total daily dose. A modified-release product would face a higher evidentiary burden because exposure, efficacy, and toxicity are closely connected for kinase inhibitors.

Potential concepts include:

• Immediate-release drug layered onto inert beads.
• Taste-masked granules.
• Gastro-resistant particles.
• Capsule-in-capsule systems.
• Lower-dose units for titration.
• Abuse-resistant or exposure-limiting packaging, although abuse is not the primary commercial issue.

These technologies are more defensible when they solve a documented administration or tolerability problem. A purely technical reformulation without a patient benefit is unlikely to support durable premium pricing.

What patents could protect a COPIKTRA reformulation?

A new duvelisib product could be protected through several patent categories:

Patent category	Potential claim subject	Expected business value
Composition of matter	Duvelisib molecule and salts	Highest barrier, generally controlled by the originator
Solid-state form	Polymorph, amorphous form, co-crystal, solvate	High if the form improves stability or manufacturability
Formulation	Excipient ratios, surfactant system, particle engineering	Moderate to high if supported by unexpected results
Dosage form	Sprinkle, liquid, dispersible, multiparticulate product	Moderate, depending on clinical differentiation
Method of use	Treatment of CLL, SLL, or follicular lymphoma	Relevant where claims remain enforceable
Manufacturing	Crystallization, purification, impurity control, encapsulation	Important for supply and freedom-to-operate
Packaging	Moisture-control system or light-protective package	Usually narrower, but useful for lifecycle management

A formulation patent should not rely solely on replacing one common excipient with another. Stronger claims would connect the excipient system to a measurable technical result, such as improved dissolution at low pH, reduced impurity formation, reduced capsule-fill variability, or longer stability under accelerated conditions.

What is the FDA regulatory status of COPIKTRA?

The FDA approved COPIKTRA on September 24, 2018, for adult patients with:

• Relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma after at least two prior therapies.
• Relapsed or refractory follicular lymphoma after at least two prior systemic therapies.[2]

The approval reflected the product's use in heavily pretreated hematologic malignancies. The label contains a boxed warning for fatal and serious toxicities, including infections, diarrhea or colitis, cutaneous reactions, pneumonitis, and hepatotoxicity.[1]

These safety risks affect excipient strategy. A formulation that improves adherence but increases peak exposure could be commercially unattractive if it worsens toxicity. Development should prioritize exposure equivalence, predictable absorption, and administration flexibility rather than aggressive bioavailability enhancement.

How does the FDA pathway affect a generic COPIKTRA product?

A conventional generic would generally pursue an abbreviated new drug application based on pharmaceutical equivalence and bioequivalence. The reference product's immediate-release capsule format is comparatively accessible to generic development.

A differentiated formulation would likely require a separate regulatory strategy, potentially involving:

• A 505(b)(2) application for a new dosage form, route, or administration method.
• Bridging pharmacokinetic studies.
• Food-effect studies.
• Comparative dissolution.
• Stability and extractables or leachables data for liquid products.
• Human factors or administration studies for sprinkle products.

The regulatory value of a new excipient is limited unless the formulation produces a clinically or operationally useful product.

What patents protect COPIKTRA and when could generic entry occur?

Duvelisib's patent estate has historically included composition-of-matter and related patent families held by the originator or its successors. The FDA Orange Book is the controlling public source for listed patents, expiration dates, pediatric extensions, and relevant exclusivity entries.[3]

The commercial assessment should separate three periods:

Period	Main barrier	Commercial implication
FDA exclusivity period	Statutory regulatory exclusivity	ANDA approval may be restricted even without patent litigation
Listed-patent period	Orange Book patents and Paragraph IV litigation	Generic approval or launch may depend on litigation outcomes
Post-exclusivity period	Remaining enforceable patents, settlements, and formulation rights	Multiple generic entrants become more likely

COPIKTRA's original approval was more than five years ago, so the five-year new chemical entity exclusivity period is no longer the principal barrier to a standard generic application. The key questions are the current Orange Book listings, patent-term adjustments, pediatric exclusivity, Paragraph IV certifications, and any settlement terms.

A generic applicant challenging a listed patent could file a Paragraph IV certification. The NDA holder could then trigger a 30-month stay by filing patent litigation within the statutory period. A settlement could establish an agreed entry date earlier than patent expiry, subject to antitrust and regulatory constraints.

What is the Orange Book status of COPIKTRA?

The Orange Book should be reviewed for the current reference listed drug, dosage strengths, patent numbers, expiration dates, and exclusivity codes.[3] The relevant product is the duvelisib capsule marketed in 15 mg and 25 mg strengths.

For diligence purposes, the Orange Book review should confirm:

1. Whether both strengths are listed under the same patent set.
2. Whether any formulation or method-of-use patents remain listed.
3. Whether the patents carry pediatric extensions.
4. Whether any patent has been delisted.
5. Whether an ANDA applicant has submitted a Paragraph IV certification.
6. Whether litigation has produced a 30-month stay or settlement-based entry date.

Patent expiration alone does not establish commercial entry timing. A generic may enter after a settlement date, after successful invalidity or non-infringement litigation, or after regulatory approval if no enforceable barrier blocks launch.

Which companies are positioned to challenge or commercialize COPIKTRA?

The commercial chain has included Verastem and specialty oncology partners, with Secura Bio associated with commercial rights and commercialization activities in the United States.[4] Generic competition would likely come from companies with oncology ANDA infrastructure, including large generic manufacturers and specialty pharmaceutical companies.

The most credible competitor profiles are:

• Generic manufacturers with existing hard-capsule oncology operations.
• Companies experienced in Paragraph IV litigation.
• Specialty firms that can support restricted-distribution or specialty-pharmacy channels.
• Formulation companies developing liquid, sprinkle, or lactose-free products.
• Regional manufacturers seeking rights outside the United States.

The size of the opportunity may limit the number of entrants. Duvelisib is used in later-line disease, and PI3K inhibitor safety concerns have constrained broad-market adoption. A generic entrant may prioritize low-cost manufacturing and rapid launch over an expensive differentiated formulation.

How strong is the COPIKTRA patent estate?

The estate is strongest where it protects the active molecule or a clinically necessary use. It is weaker against a conventional generic if the reference capsule uses ordinary excipients and the generic can design around nonessential formulation details.

A practical strength assessment is:

Asset	Relative strength	Reason
Core molecule patent	High, if unexpired and enforceable	Difficult to design around without using a different active ingredient
Approved-use patent	Moderate	Vulnerable to skinny-label strategies and claim construction
Immediate-release capsule formulation	Low to moderate	Conventional excipient systems are often design-around candidates
Liquid or sprinkle formulation	Potentially high	Can create a separate product-specific barrier
Manufacturing process	Moderate	Useful if impurity control is difficult to reproduce
Packaging claim	Low to moderate	Narrow scope but can complicate exact copying

The strongest lifecycle strategy would combine a differentiated dosage form with a method-of-use claim tied to a defined patient population or dosing regimen. A formulation patent without clinical utility would have limited defensive value.

What commercial opportunities exist beyond a conventional generic?

Specialty-pharmacy supply and access

COPIKTRA is used in a specialty oncology setting. Reliable supply, patient-support services, refill coordination, and prior-authorization assistance can be as important as excipient differentiation. A lower-cost supplier could compete through continuity of supply and payer access.

Regional excipient compliance

A lactose-free or gelatin-free product could support selected international markets. Capsule-shell substitution with hypromellose may improve vegetarian acceptance and reduce dependence on animal-derived gelatin. The commercial benefit depends on local registration requirements, capsule-shell performance, and whether the change requires a new clinical bridge.

Hospital dosage flexibility

A lower-strength unit, dispersible product, or oral liquid could address treatment interruptions and dose reductions. This is relevant because duvelisib toxicity management can involve interruption or dose modification under the prescribing information.[1]

Contract manufacturing

Manufacturers with validated low-dose encapsulation, potent-compound containment, and oncology packaging capabilities could pursue contract development and manufacturing opportunities. The process challenge is not capsule filling alone. It includes containment, cleaning validation, blend uniformity, impurity control, and supply continuity for a relatively specialized product.

Out-licensing and regional rights

A company holding a differentiated duvelisib formulation could license territory-specific rights to specialty oncology distributors. A conventional generic has less licensing leverage unless it has an early-entry settlement, reliable supply, or a cost advantage.

What generic launch scenarios exist for COPIKTRA?

Scenario	Likely product	Commercial effect
First generic after patent clearance	15 mg and 25 mg immediate-release capsules	Meaningful price erosion and rapid payer substitution
Authorized generic or licensed generic	Same or near-identical capsule	Moderates first-wave competition
Multiple generic entrants	Standard capsules	Steep price decline and limited formulation premiums
Differentiated 505(b)(2) product	Liquid, sprinkle, or lactose-free capsule	Smaller but higher-margin niche
Settlement-based entry	Authorized date before full patent expiry	Predictable erosion beginning on the settlement date
Regional-only launch	Local generic or licensed product	Geographic fragmentation and variable pricing

A standard generic is the most probable competitive threat because the dosage form is a conventional immediate-release capsule. A reformulated product is more likely to create incremental value than to block generic erosion across the entire market.

How does COPIKTRA compare with other PI3K inhibitors?

Duvelisib competes within a safety-sensitive class that includes idelalisib and other PI3K-pathway therapies. The comparison is not based only on dose form or excipients.

Product	Active ingredient	Main formulation	Commercial relevance
COPIKTRA	Duvelisib	Immediate-release hard capsule	Reformulation opportunity in later-line hematologic disease
ZYDELIG	Idelalisib	Immediate-release tablet	Competing PI3K-delta product with its own safety and patent history
PIQRAY	Alpelisib	Immediate-release tablet	Solid-tumor indication and different commercial market
TRUQAP	Capivasertib	Immediate-release tablet	Different kinase target and tumor indications

COPIKTRA's capsule format may be easier to reproduce than a complex tablet, but the later-line patient population is narrower. Commercial success therefore depends on manufacturing cost, reimbursement, supply reliability, and differentiated administration rather than on broad primary-care demand.

Key Takeaways

• COPIKTRA contains a conventional immediate-release capsule excipient system centered on lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, magnesium stearate, colloidal silicon dioxide, sodium lauryl sulfate, and talc.
• The strongest formulation opportunities are lactose-free capsules, reduced-surfactant systems, sprinkle products, oral liquids, and dose-flexible multiparticulates.
• A conventional generic capsule is technically more accessible than a modified-release or liquid product.
• COPIKTRA's safety profile makes exposure control and predictable absorption more valuable than aggressive bioavailability enhancement.
• The five-year new chemical entity exclusivity period is no longer the primary U.S. barrier. Current Orange Book patents, Paragraph IV challenges, litigation, settlements, and pediatric exclusivity control entry timing.
• Formulation patents are more defensible when tied to improved stability, dissolution, impurity control, or a clinically useful administration method.
• The commercial market is specialty-oriented and likely supports a limited number of differentiated entrants rather than a large premium-formulation market.

FAQs About COPIKTRA Excipients and Commercial Strategy

Can COPIKTRA be reformulated without lactose?

Yes. Lactose can potentially be replaced with microcrystalline cellulose, mannitol, dibasic calcium phosphate, or another compatible filler. The replacement must be supported by comparative dissolution, stability, impurity, and capsule-fill data.

Is a gelatin-free COPIKTRA capsule commercially viable?

Potentially. A hypromellose capsule could address vegetarian, religious, and animal-origin preferences. The opportunity is strongest in markets where gelatin restrictions affect procurement or patient acceptance.

Could a generic manufacturer sell COPIKTRA as an oral liquid?

A liquid product would generally require a separate regulatory strategy rather than a routine ANDA based only on the reference capsule. Solubility, stability, preservative compatibility, dose uniformity, and container performance would determine feasibility.

Would an SLS-free duvelisib formulation have patent value?

It could, but removal alone is unlikely to create strong protection. Patent value would be higher if the SLS-free system produced unexpected dissolution, stability, tolerability, or bioavailability results.

What is the most attractive commercial opportunity for a COPIKTRA competitor?

A low-cost immediate-release generic is the most direct volume opportunity. A lactose-free, gelatin-free, sprinkle-compatible, or liquid formulation is the more defensible niche if supported by patient-use data and a clear regulatory pathway.

References

1. U.S. Food and Drug Administration. (2024). COPIKTRA (duvelisib) capsules, prescribing information.
2. U.S. Food and Drug Administration. (2018, September 24). FDA approves duvelisib for relapsed or refractory CLL/SLL and follicular lymphoma.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
4. Secura Bio, Inc. (n.d.). COPIKTRA (duvelisib) product information.